A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition
British Journal of Clinical Pharmacology2018Vol. 84(10), pp. 2270–2279
Citations Over TimeTop 18% of 2018 papers
Valérie Cuvier, Ulrike Lorch, Stephan Witte, Aurélie Olivier, Sébastien Gibot, Isabelle Delor, Jean–Jacques Garaud, Marc Derive, Margarita Salcedo‐Magguilli
Abstract
The novel immunomodulator nangibotide displayed favourable safety and PK profiles at all doses, including expected pharmacologically active doses, and warrants further clinical development.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- → Place of Voltaren in clinical practice: emphasis on its tolerability(2009)1 cited
- → TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS(2017)